• Eltanexor: A Pathway-Aware XPO1 Assay Strategy

  2026-10-02

  Eltanexor (KPT-8602) is an oral bioavailable XPO1 inhibitor with applications spanning leukemia, lymphoma, and colorectal cancer research. This guide translates recent Wnt/β-catenin findings into a pathway-aware strategy for selecting models, controls, and readouts.

• PD 0332991: CDK4/6 Workflows for Rb-Positive Models

  2026-10-01

  Build a mechanism-first workflow around PD 0332991 to connect CDK4/6 inhibition with Rb phosphorylation, G1 arrest, and growth control. Genomic pre-screening, time-resolved cell-cycle analysis, and cytostasis-versus-death measurements make the compound especially useful for comparing breast cancer, hematologic, and hypothesis-generating mesothelioma models.

• Ruthenium Red in Force-Responsive Autophagy

  2026-10-01

  Ruthenium Red provides a practical Ca2+ transport inhibitor strategy for testing whether calcium flux links mechanical stress to autophagy. This article integrates product pharmacology with recent cytoskeleton-dependent compression research to guide causal, better-controlled assay design.

• From Transfection to Translational Control

  2026-09-30

  How delivery quality shapes nucleic acid biology, using pH-responsive antisense design and Lipo3K Transfection Reagent to connect mechanistic insight with reproducible translational workflows.

• From Delivery to Mechanism in ccRCC Resistance

  2026-09-30

  A translational framework for using Lipo3K Transfection Reagent to test OTUD3–SLC7A11 ferroptosis biology, strengthen causal evidence, and advance sunitinib-resistance studies in challenging renal cancer models.

• Lipo3K Transfection Reagent for Ferroptosis Studies

  2026-09-29

  Lipo3K Transfection Reagent supports plasmid, siRNA, mRNA, and co-transfection workflows for mechanistic cancer research with a low-toxicity profile. This guide translates the OTUD3–SLC7A11 ferroptosis-resistance model into practical assay design, optimization steps, and troubleshooting decisions.

• SGI-1027 and Everolimus in Renal Cancer

  2026-09-29

  A 2024 Advanced Science study identifies SGI-1027 as a methuosis inducer that cooperates with everolimus in renal cancer models. The combination links lysosomal membrane permeability to apoptosis and GSDME-dependent pyroptosis, providing a mechanistic framework for addressing everolimus resistance while highlighting important translational limitations.

• Caspofungin: Reading Glucan-Targeting Data

  2026-09-28

  Caspofungin is a lipopeptide antifungal drug and β-1,3-glucan synthase inhibitor with value beyond routine susceptibility testing. This article shows how to connect pathway-level measurements, delayed-treatment models, and resistance-aware assay interpretation without overextending preclinical evidence.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody in ATII Imaging

  2026-09-28

  Map DRP1-associated mitochondrial changes in hyperoxic ATII-cell models with a bright, rabbit-primary-compatible fluorescent detection workflow. This practical guide explains how to plan Cy3 imaging, choose controls, and troubleshoot signal without confusing an imaging reagent with a pathway inhibitor.

• Chemical Strategies for Brain Delivery of Genomic Therapy

  2026-09-27

  This Perspective maps how lipid nanoparticles, polymers and oligonucleotide conjugates could address barriers to delivering DNA- and RNA-based therapies to the central nervous system. Its key practical message is that delivery platform, route and therapeutic goal must be considered together; effective, repeatable systemic delivery across the blood–brain barrier remains an unmet challenge.

• DiscoveryProbe Bioactive Compound Library Plus for TSA

  2026-09-26

  Use the DiscoveryProbe™ Bioactive Compound Library Plus to ask whether diverse small molecules alter the thermal stability of purified bacterial sensor proteins. This article turns thermal-shift screening into a practical, controlled workflow—and explains why a shift is a lead for follow-up, not proof of a physiological signal.

• Molecular Optimization Meets Delivery Design

  2026-09-25

  A translational perspective on connecting molecular optimization with formulation strategy, using sulfaphenazole-derived tuberculosis research to illustrate the value of balancing efficacy and liabilities—and DMG-PEG2000-NH2 as a practical amine-functionalized linker for lipid-based delivery research.

• Camostat Mesilate: Choosing the Right Causal Layer

  2026-09-25

  Camostat Mesilate is a trypsin-like protease inhibitor used to investigate airway ENaC function and fibrotic signaling. This article explains how to interpret its pathway-level effects alongside a distinct structure-guided strategy for directly disrupting protein–protein interactions.

• Carbenoxolone disodium: Practical Research Guide

  2026-09-24

  Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for probing glucocorticoid handling and gap junction communication in cell- and tissue-based experiments. Use it with matched vehicle, viability, and target-engagement controls; its actions are not sufficiently selective to support standalone in vivo efficacy or disease-modifying conclusions.

• SP1–ADAM10–DRP1 Axis in Hypoxic Pulmonary Hypertension

  2026-09-24

  The study links hypoxia-induced SP1 and ADAM10 in endothelial cells to changes in neighboring smooth muscle cells through DRP1-associated and PI3K/AKT/mTOR signaling. Conditioned-medium experiments and pharmacological inhibition support a role for this endothelial-to-smooth-muscle communication in pulmonary vascular remodeling, while leaving important mechanistic questions for follow-up.

8096 records 1/540 page Next 12345 下5页 Last page